Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Psychol Med

Retrieve available abstracts of 180 articles:
HTML format

Single Articles

    June 2022
  1. TOWNSEND L, Pillinger T, Selvaggi P, Veronese M, et al
    Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of (18)FDG-PET studies in schizophrenia.
    Psychol Med. 2022 Jun 22:1-18. doi: 10.1017/S003329172200174.
    PubMed     Abstract available

  2. FUENTES-CLARAMONTE P, Salgado-Pineda P, Argila-Plaza I, Garcia-Leon MA, et al
    Neural correlates of referential/persecutory delusions in schizophrenia: examination using fMRI and a virtual reality underground travel paradigm.
    Psychol Med. 2022 Jun 22:1-8. doi: 10.1017/S0033291722001751.
    PubMed     Abstract available

  3. DE HAAN L, Linszen D, Wouters L, Zwinderman K, et al
    Sustained specialized and family treatment in first-episode schizophrenia or related disorders: a 5-year randomized controlled trial.
    Psychol Med. 2022 Jun 8:1-8. doi: 10.1017/S003329172200099.
    PubMed     Abstract available

  4. RABALLO A, Poletti M, Preti A
    Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis.
    Psychol Med. 2022 Jun 3:1-11. doi: 10.1017/S0033291722001428.
    PubMed     Abstract available

    May 2022
  5. HOMAN P, Schooler NR, Brunette MF, Rotondi A, et al
    Relapse prevention through health technology program reduces hospitalization in schizophrenia.
    Psychol Med. 2022 May 30:1-7. doi: 10.1017/S0033291722000794.
    PubMed     Abstract available

  6. DESOUZA DD, Tang SX, Danilewitz M
    The burgeoning role of speech and language assessment in schizophrenia spectrum disorders.
    Psychol Med. 2022 May 18:1-2. doi: 10.1017/S0033291722001325.

  7. CULBERT KM, Thakkar KN, Klump KL
    Risk for midlife psychosis in women: critical gaps and opportunities in exploring perimenopause and ovarian hormones as mechanisms of risk.
    Psychol Med. 2022 May 18:1-9. doi: 10.1017/S0033291722001143.
    PubMed     Abstract available

  8. CZEPIELEWSKI LS, Alliende LM, Castaneda CP, Castro M, et al
    Effects of Socioeconomic Status in Cognition of People with Schizophrenia: Results From a Latin American Collaboration Network with 1175 Subjects - Corrigendum.
    Psychol Med. 2022 May 9:1. doi: 10.1017/S0033291721003949.

    Risk of psychosis among migrants to the Netherlands by time since arrival.
    Psychol Med. 2022 May 5:1-10. doi: 10.1017/S0033291722001192.
    PubMed     Abstract available

    April 2022
  10. BADAL VD, Depp CA, Harvey PD, Ackerman RA, et al
    Confidence, accuracy judgments and feedback in schizophrenia and bipolar disorder: a time series network analysis.
    Psychol Med. 2022 Apr 28:1-10. doi: 10.1017/S0033291722000939.
    PubMed     Abstract available

  11. FREEMAN D, Rosebrock L, Waite F, Loe BS, et al
    Virtual reality (VR) therapy for patients with psychosis: satisfaction and side effects.
    Psychol Med. 2022 Apr 28:1-12. doi: 10.1017/S0033291722001167.
    PubMed     Abstract available

  12. CATALAN A, Aymerich C, Bilbao A, Pedruzo B, et al
    Psychosis and Substance Abuse increase the COVID-19 mortality risk.
    Psychol Med. 2022 Apr 12:1-23. doi: 10.1017/S0033291722000976.

  13. JANG SK, Saunders G, Liu M, Jiang Y, et al
    Genetic correlation, pleiotropy, and causal associations between substance use and psychiatric disorder.
    Psychol Med. 2022;52:968-978.
    PubMed     Abstract available

    March 2022
  14. ROBINSON T, Ali MU, Easterbrook B, Hall W, et al
    Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis.
    Psychol Med. 2022 Mar 24:1-11. doi: 10.1017/S0033291722000502.
    PubMed     Abstract available

  15. VITA A, Barlati S, Ceraso A, Deste G, et al
    Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Psychol Med. 2022 Mar 8:1-11. doi: 10.1017/S0033291722000319.
    PubMed     Abstract available

  16. FLAATEN CB, Melle I, Gardsjord E, Bjella T, et al
    Course of intellectual functioning in schizophrenia and bipolar disorder: a 10-year follow-up study.
    Psychol Med. 2022 Mar 8:1-9. doi: 10.1017/S0033291721004645.
    PubMed     Abstract available

    February 2022
  17. DEMJAHA A, Galderisi S, Glenthoj B, Arango C, et al
    Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study.
    Psychol Med. 2022 Feb 24:1-9. doi: 10.1017/S0033291722000010.
    PubMed     Abstract available

  18. HUANG LC, Lin SH, Tseng HH, Chen KC, et al
    Altered glutamate level and its association with working memory among patients with treatment-resistant schizophrenia (TRS): a proton magnetic resonance spectroscopy study.
    Psychol Med. 2022 Feb 24:1-8. doi: 10.1017/S003329172100533.
    PubMed     Abstract available

  19. WATSON AJ, Giordano A, Suckling J, Barnes TRE, et al
    Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markers.
    Psychol Med. 2022 Feb 18:1-10. doi: 10.1017/S0033291721004815.
    PubMed     Abstract available

  20. LI M, Deng W, Li Y, Zhao L, et al
    Ameliorative patterns of grey matter in patients with first-episode and treatment-naive schizophrenia.
    Psychol Med. 2022 Feb 15:1-11. doi: 10.1017/S0033291722000058.
    PubMed     Abstract available

  21. DENG W, Addington J, Bearden CE, Cadenhead KS, et al
    Characterizing sustained social anxiety in individuals at clinical high risk for psychosis: trajectory, risk factors, and functional outcomes.
    Psychol Med. 2022 Feb 11:1-8. doi: 10.1017/S0033291722000277.
    PubMed     Abstract available

  22. HUI CLM, Wong AKH, Ho ECN, Lam BST, et al
    Effectiveness and optimal duration of early intervention treatment in adult-onset psychosis: a randomized clinical trial.
    Psychol Med. 2022 Feb 11:1-13. doi: 10.1017/S0033291721004189.
    PubMed     Abstract available

  23. DAN-GLAUSER E, Framorando D, Solida-Tozzi A, Golay P, et al
    Evolution of impulsivity levels in relation to early cannabis use in violent patients in the early phase of psychosis.
    Psychol Med. 2022 Feb 10:1-10. doi: 10.1017/S0033291721005316.
    PubMed     Abstract available

  24. PICO-PEREZ M, Vieira R, Fernandez-Rodriguez M, De Barros MAP, et al
    Multimodal meta-analysis of structural gray matter, neurocognitive and social cognitive fMRI findings in schizophrenia patients.
    Psychol Med. 2022 Feb 7:1-11. doi: 10.1017/S0033291721005523.
    PubMed     Abstract available

  25. WILKINSON ID, Mahmood T, Yasmin SF, Tomlinson A, et al
    In memory of Professor Iain Wilkinson: cognitive and neuroimaging endophenotypes in a consanguineous schizophrenia multiplex family.
    Psychol Med. 2022 Feb 7:1-9. doi: 10.1017/S0033291721005250.
    PubMed     Abstract available

    January 2022
  26. RODRIGUEZ V, Alameda L, Quattrone D, Tripoli G, et al
    Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study.
    Psychol Med. 2022 Jan 25:1-10. doi: 10.1017/S0033291721005456.
    PubMed     Abstract available

  27. LEPAGE M, Bowie CR, Montreuil T, Baer L, et al
    Manualized group cognitive behavioral therapy for social anxiety in first-episode psychosis: a randomized controlled trial.
    Psychol Med. 2022 Jan 11:1-10. doi: 10.1017/S0033291721005328.
    PubMed     Abstract available

  28. SU W, Yuan A, Tang Y, Xu L, et al
    Effects of polygenic risk of schizophrenia on interhemispheric callosal white matter integrity and frontotemporal functional connectivity in first-episode schizophrenia.
    Psychol Med. 2022 Jan 7:1-10. doi: 10.1017/S0033291721004840.
    PubMed     Abstract available

  29. SCHICK A, van Winkel R, Lin BD, Luykx JJ, et al
    Polygenic risk, familial liability and stress reactivity in psychosis: an experience sampling study.
    Psychol Med. 2022 Jan 7:1-10. doi: 10.1017/S0033291721004761.
    PubMed     Abstract available

    November 2021
  30. ROTENBERG M, Tuck A, Anderson KK, McKenzie K, et al
    Neighbourhood-level social capital, marginalisation, and the incidence of schizophrenia and schizoaffective disorder in Toronto, Canada: a retrospective population-based cohort study.
    Psychol Med. 2021 Nov 23:1-9. doi: 10.1017/S003329172100458.
    PubMed     Abstract available

  31. ERZIN G, Pries LK, Dimitrakopoulos S, Ralli I, et al
    Association between exposome score for schizophrenia and functioning in first-episode psychosis: results from the Athens first-episode psychosis research study.
    Psychol Med. 2021 Nov 18:1-10. doi: 10.1017/S0033291721004542.
    PubMed     Abstract available

  32. BRAND BA, Haveman YRA, de Beer F, de Boer JN, et al
    Antipsychotic medication for women with schizophrenia spectrum disorders.
    Psychol Med. 2021 Nov 12:1-15. doi: 10.1017/S0033291721004591.
    PubMed     Abstract available

  33. MERCHANT JT, Moran EK, Strube MJ, Barch DM, et al
    Correlates of real-world goal-directed behavior in schizophrenia.
    Psychol Med. 2021 Nov 12:1-9. doi: 10.1017/S0033291721004281.
    PubMed     Abstract available

  34. HODGINS S, Eronen M, Freese R, Hart S, et al
    Correspondence regarding De Girolamo et al., 2021 'A multinational case-control study comparing forensic and non-forensic patients with schizophrenia spectrum disorders: the EU-VIORMED project'.
    Psychol Med. 2021 Nov 2:1-2. doi: 10.1017/S0033291721004347.

    Commentary: the ethical challenges of machine learning in psychiatry: a focus on data, diagnosis, and treatment.
    Psychol Med. 2021;51:2522-2524.
    PubMed     Abstract available

    October 2021
  36. OOMEN PP, Begemann MJH, Brand BA, de Haan L, et al
    Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis.
    Psychol Med. 2021 Oct 19:1-11. doi: 10.1017/S0033291721004153.
    PubMed     Abstract available

  37. LO LLH, Lee EHM, Hui CLM, Chong CSY, et al
    Effect of high-endurance exercise intervention on sleep-dependent procedural memory consolidation in individuals with schizophrenia: a randomized controlled trial.
    Psychol Med. 2021 Oct 7:1-13. doi: 10.1017/S0033291721003196.
    PubMed     Abstract available

    September 2021
  38. SHENG D, Pu W, Linli Z, Tian GL, et al
    Aberrant global and local dynamic properties in schizophrenia with instantaneous phase method based on Hilbert transform.
    Psychol Med. 2021 Sep 30:1-11. doi: 10.1017/S0033291721003895.
    PubMed     Abstract available

  39. EMSLEY R, du Plessis S, Phahladira L, Luckhoff HK, et al
    Antipsychotic treatment effects and structural MRI brain changes in schizophrenia.
    Psychol Med. 2021 Sep 23:1-10. doi: 10.1017/S0033291721003809.
    PubMed     Abstract available

  40. PAQUIN V, Cupo L, Malla AK, Iyer SN, et al
    Dynamic association of the first identifiable symptom with rapidity of progression to first-episode psychosis.
    Psychol Med. 2021 Sep 20:1-9. doi: 10.1017/S0033291721003755.
    PubMed     Abstract available

  41. DE GIROLAMO G, Iozzino L, Ferrari C, Gosek P, et al
    A multinational case-control study comparing forensic and non-forensic patients with schizophrenia spectrum disorders: the EU-VIORMED project.
    Psychol Med. 2021 Sep 13:1-11. doi: 10.1017/S0033291721003433.
    PubMed     Abstract available

  42. GARRIDO-TORRES N, Rocha-Gonzalez I, Alameda L, Rodriguez-Gangoso A, et al
    Metabolic syndrome in antipsychotic-naive patients with first-episode psychosis: a systematic review and meta-analysis.
    Psychol Med. 2021 Sep 8:1-14. doi: 10.1017/S0033291721002853.
    PubMed     Abstract available

  43. LI X, Deng W, Xue R, Wang Q, et al
    Auditory event-related potentials, neurocognition, and global functioning in drug naive first-episode schizophrenia and bipolar disorder.
    Psychol Med. 2021 Sep 3:1-10. doi: 10.1017/S0033291721002130.
    PubMed     Abstract available

  44. FRAWLEY E, Cowman M, Lepage M, Donohoe G, et al
    Social and occupational recovery in early psychosis: a systematic review and meta-analysis of psychosocial interventions.
    Psychol Med. 2021 Sep 3:1-12. doi: 10.1017/S003329172100341.
    PubMed     Abstract available

  45. HJERN A, Palacios J, Vinnerljung B
    Early childhood adversity and non-affective psychosis: a study of refugees and international adoptees in Sweden.
    Psychol Med. 2021 Sep 2:1-10. doi: 10.1017/S003329172100355.
    PubMed     Abstract available

    August 2021
  46. MARTLAND R, Teasdale S, Murray RM, Gardner-Sood P, et al
    Dietary intake, physical activity and sedentary behaviour patterns in a sample with established psychosis and associations with mental health symptomatology.
    Psychol Med. 2021 Aug 23:1-11. doi: 10.1017/S0033291721003147.
    PubMed     Abstract available

  47. ALLARDYCE J, Hollander AC, Rahman S, Dalman C, et al
    Association of trauma, post-traumatic stress disorder and non-affective psychosis across the life course: a nationwide prospective cohort study.
    Psychol Med. 2021 Aug 20:1-9. doi: 10.1017/S0033291721003287.
    PubMed     Abstract available

  48. COORS A, Imtiaz MA, Boenniger MM, Aziz NA, et al
    Polygenic risk scores for schizophrenia are associated with oculomotor endophenotypes.
    Psychol Med. 2021 Aug 20:1-9. doi: 10.1017/S0033291721003251.
    PubMed     Abstract available

  49. MOFFA G, Kuipers J, Carra G, Crocamo C, et al
    Longitudinal symptomatic interactions in long-standing schizophrenia: a novel five-point analysis based on directed acyclic graphs.
    Psychol Med. 2021 Aug 5:1-8. doi: 10.1017/S0033291721002920.
    PubMed     Abstract available

  50. DE BOER JN, Voppel AE, Brederoo SG, Schnack HG, et al
    Acoustic speech markers for schizophrenia-spectrum disorders: a diagnostic and symptom-recognition tool.
    Psychol Med. 2021 Aug 4:1-11. doi: 10.1017/S0033291721002804.
    PubMed     Abstract available

  51. ZHAO W, Zhang Q, Chen X, Li Y, et al
    The VNTR of the AS3MT gene is associated with brain activations during a memory span task and their training-induced plasticity.
    Psychol Med. 2021;51:1927-1932.
    PubMed     Abstract available

    July 2021
  52. WIESSNER I, Falchi M, Palhano-Fontes F, Feilding A, et al
    LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model.
    Psychol Med. 2021 Jul 13:1-15. doi: 10.1017/S0033291721002531.
    PubMed     Abstract available

  53. JOHNSON EC, Kapoor M, Hatoum AS, Zhou H, et al
    Investigation of convergent and divergent genetic influences underlying schizophrenia and alcohol use disorder.
    Psychol Med. 2021 Jul 7:1-9. doi: 10.1017/S003329172100266.
    PubMed     Abstract available

  54. FAGERLUND B, Pantelis C, Jepsen JRM, Raghava JM, et al
    Differential effects of age at illness onset on verbal memory functions in antipsychotic-naive schizophrenia patients aged 12-43 years.
    Psychol Med. 2021;51:1570-1580.
    PubMed     Abstract available

  55. NEUMANN SR, Glue P, Linscott RJ
    Aberrant salience and reward processing: a comparison of measures in schizophrenia and anxiety.
    Psychol Med. 2021;51:1507-1515.
    PubMed     Abstract available

  56. JONGSMA HE, Gayer-Anderson C, Tarricone I, Velthorst E, et al
    Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study.
    Psychol Med. 2021;51:1536-1548.
    PubMed     Abstract available

  57. LIEBERS DT, Pirooznia M, Ganna A, Goes FS, et al
    Discriminating bipolar depression from major depressive disorder with polygenic risk scores.
    Psychol Med. 2021;51:1451-1458.
    PubMed     Abstract available

  58. CHRETIEN B, Lelong-Boulouard V, Chantepie S, Sassier M, et al
    Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase((R)).
    Psychol Med. 2021;51:1459-1466.
    PubMed     Abstract available

  59. RAUSCHENBERG C, Reininghaus U, Ten Have M, de Graaf R, et al
    The jumping to conclusions reasoning bias as a cognitive factor contributing to psychosis progression and persistence: findings from NEMESIS-2.
    Psychol Med. 2021;51:1696-1703.
    PubMed     Abstract available

  60. KOWALCZYK OS, Pauls AM, Fuste M, Williams SCR, et al
    Neurocognitive correlates of working memory and emotional processing in postpartum psychosis: an fMRI study.
    Psychol Med. 2021;51:1724-1732.
    PubMed     Abstract available

  61. CUESTA MJ, Lecumberri P, Moreno-Izco L, Lopez-Ilundain JM, et al
    Motor abnormalities and basal ganglia in first-episode psychosis (FEP).
    Psychol Med. 2021;51:1625-1636.
    PubMed     Abstract available

    June 2021
  62. CZEPIELEWSKI LS, Alliende LM, Castaneda CP, Castro M, et al
    Effects of socioeconomic status in cognition of people with schizophrenia: results from a Latin American collaboration network with 1175 subjects.
    Psychol Med. 2021 Jun 23:1-12. doi: 10.1017/S0033291721002403.
    PubMed     Abstract available

  63. SCHOFIELD P, Das-Munshi J, Webb RT, Horsdal HT, et al
    Lack of fit with the neighbourhood social environment as a risk factor for psychosis - a national cohort study.
    Psychol Med. 2021 Jun 18:1-9. doi: 10.1017/S0033291721002233.
    PubMed     Abstract available

  64. STRAUSS GP, Bartolomeo LA, Luther L
    Reduced willingness to expend effort for rewards is associated with risk for conversion and negative symptom severity in youth at clinical high-risk for psychosis.
    Psychol Med. 2021 Jun 14:1-8. doi: 10.1017/S003329172100204.
    PubMed     Abstract available

  65. DONG D, Yao D, Wang Y, Hong SJ, et al
    Compressed sensorimotor-to-transmodal hierarchical organization in schizophrenia.
    Psychol Med. 2021 Jun 8:1-14. doi: 10.1017/S0033291721002129.
    PubMed     Abstract available

    May 2021
  66. STAFFORD J, Dykxhoorn J, Sommerlad A, Dalman C, et al
    Association between risk of dementia and very late-onset schizophrenia-like psychosis: a Swedish population-based cohort study.
    Psychol Med. 2021 May 25:1-9. doi: 10.1017/S0033291721002099.
    PubMed     Abstract available

  67. O'DONOGHUE B, Lyne J, Roche E, Mifsud N, et al
    Risk of first-episode psychosis in migrants to the Republic of Ireland.
    Psychol Med. 2021 May 25:1-8. doi: 10.1017/S003329172100177.
    PubMed     Abstract available

  68. LINDGREN M, Kuvaja H, Jokela M, Therman S, et al
    Predictive validity of psychosis risk models when applied to adolescent psychiatric patients.
    Psychol Med. 2021 May 24:1-12. doi: 10.1017/S0033291721001938.
    PubMed     Abstract available

  69. AYESA-ARRIOLA R, Miguel-Corredera M, de la Foz VO, Neergaard KD, et al
    Education and long-term outcomes in first episode psychosis: 10-year follow-up study of the PAFIP cohort.
    Psychol Med. 2021 May 6:1-12. doi: 10.1017/S0033291721001112.
    PubMed     Abstract available

  70. WEARNE TA, McDonald S
    Social cognition v. emotional intelligence in first-episode psychosis: are they the same?
    Psychol Med. 2021;51:1229-1230.

    April 2021
  71. ZHANG R, Kuja-Halkola R, Birgegard A, Larsson H, et al
    Association of family history of schizophrenia and clinical outcomes in individuals with eating disorders.
    Psychol Med. 2021 Apr 30:1-8. doi: 10.1017/S0033291721001574.
    PubMed     Abstract available

  72. MCHUGO M, Avery S, Armstrong K, Rogers BP, et al
    Anterior hippocampal dysfunction in early psychosis: a 2-year follow-up study.
    Psychol Med. 2021 Apr 20:1-10. doi: 10.1017/S0033291721001318.
    PubMed     Abstract available

  73. SEDGWICK O, Hardy A, Newbery K, Cella M, et al
    A systematic review of adherence to group interventions in psychosis: do people attend?
    Psychol Med. 2021 Apr 16:1-9. doi: 10.1017/S0033291721000404.
    PubMed     Abstract available

  74. JOO SW, Kim H, Jo YT, Choi YJ, et al
    Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study.
    Psychol Med. 2021 Apr 15:1-8. doi: 10.1017/S0033291721001379.
    PubMed     Abstract available

  75. SWERDLOW NR, Bhakta SG, Talledo J, Benster L, et al
    Auditory discrimination and frequency modulation learning in schizophrenia patients: amphetamine within-subject dose response and time course.
    Psychol Med. 2021 Apr 14:1-9. doi: 10.1017/S0033291721001239.
    PubMed     Abstract available

  76. VAN LEEUWEN JMC, Vinkers CH, Vink M, Kahn RS, et al
    Disrupted upregulation of salience network connectivity during acute stress in siblings of schizophrenia patients.
    Psychol Med. 2021;51:1038-1048.
    PubMed     Abstract available

  77. GUO JY, Lesh TA, Niendam TA, Ragland JD, et al
    Brain free water alterations in first-episode psychosis: a longitudinal analysis of diagnosis, course of illness, and medication effects.
    Psychol Med. 2021;51:1001-1010.
    PubMed     Abstract available

  78. POKORNY VJ, Lano TJ, Schallmo MP, Olman CA, et al
    Reduced influence of perceptual context in schizophrenia: behavioral and neurophysiological evidence.
    Psychol Med. 2021;51:786-794.
    PubMed     Abstract available

  79. PEREZ J, Jones PB
    Breaking the web: life beyond the at-risk mental state for psychosis.
    Psychol Med. 2021;51:934-939.
    PubMed     Abstract available

    March 2021
  80. CORSI-ZUELLI F, Marques L, da Roza DL, Loureiro CM, et al
    The independent and combined effects of cannabis use and systemic inflammation during the early stages of psychosis: exploring the two-hit hypothesis.
    Psychol Med. 2021 Mar 19:1-11. doi: 10.1017/S0033291721000726.
    PubMed     Abstract available

  81. HARPER J, Liu M, Malone SM, McGue M, et al
    Using multivariate endophenotypes to identify psychophysiological mechanisms associated with polygenic scores for substance use, schizophrenia, and education attainment.
    Psychol Med. 2021 Mar 18:1-11. doi: 10.1017/S0033291721000763.
    PubMed     Abstract available

  82. DENG F, Phillips MR, Cai B, Yu G, et al
    Comparison of social cognition using an adapted Chinese version of the Reading the Mind in the Eyes Test in drug-naive and regularly medicated individuals with chronic schizophrenia and healthy controls in rural China.
    Psychol Med. 2021 Mar 16:1-13. doi: 10.1017/S003329172100043.
    PubMed     Abstract available

  83. FRYER SL, Ferri JM, Roach BJ, Loewy RL, et al
    Thalamic dysconnectivity in the psychosis risk syndrome and early illness schizophrenia.
    Psychol Med. 2021 Mar 15:1-9. doi: 10.1017/S0033291720004882.
    PubMed     Abstract available

  84. TAN EJ, Rossell SL, Subotnik KL, Ventura J, et al
    Cognitive heterogeneity in first-episode psychosis and its relationship with premorbid developmental adjustment.
    Psychol Med. 2021 Mar 12:1-10. doi: 10.1017/S0033291721000738.
    PubMed     Abstract available

  85. WORTINGER LA, Jorgensen KN, Barth C, Nerland S, et al
    Significant association between intracranial volume and verbal intellectual abilities in patients with schizophrenia and a history of birth asphyxia.
    Psychol Med. 2021 Mar 10:1-10. doi: 10.1017/S0033291721000489.
    PubMed     Abstract available

  86. CHEN KC, Yang YK, Howes OD, Lee IH, et al
    Striatal dopamine D2/3 receptors in medication-naive schizophrenia: an [(123)I] IBZM SPECT study.
    Psychol Med. 2021 Mar 8:1-9. doi: 10.1017/S0033291720005413.
    PubMed     Abstract available

  87. KLIPPEL A, Schick A, Myin-Germeys I, Rauschenberg C, et al
    Modelling the temporal interplay between stress and affective disturbances in pathways to psychosis: an experience sampling study.
    Psychol Med. 2021 Mar 8:1-10. doi: 10.1017/S0033291720004894.
    PubMed     Abstract available

  88. GAULD C, Micoulaud-Franchi JA, Dumas G
    Comment on Starke et al.: "Computing schizophrenia: ethical challenges for machine learning in psychiatry": From machine learning to student learning: pedagogical challenges for psychiatry - Corrigendum.
    Psychol Med. 2021 Mar 4:1. doi: 10.1017/S0033291721000684.

  89. CAKICI N, Sutterland AL, Penninx BWJH, de Haan L, et al
    Changes in peripheral blood compounds following psychopharmacological treatment in drug-naive first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis.
    Psychol Med. 2021 Mar 3:1-12. doi: 10.1017/S0033291721000155.
    PubMed     Abstract available

  90. MISRA S, Gelaye B, Williams DR, Koenen KC, et al
    Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case-control study.
    Psychol Med. 2021 Mar 2:1-9. doi: 10.1017/S0033291721000453.
    PubMed     Abstract available

  91. O'NEILL A, Wilson R, Blest-Hopley G, Annibale L, et al
    Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
    Psychol Med. 2021;51:596-606.
    PubMed     Abstract available

  92. HUANG MH, Cheng CM, Tsai SJ, Bai YM, et al
    Familial coaggregation of major psychiatric disorders among first-degree relatives of patients with obsessive-compulsive disorder: a nationwide study.
    Psychol Med. 2021;51:680-687.
    PubMed     Abstract available

  93. NKIRE N, Scully PJ, Browne DJ, Baldwin PA, et al
    Systematic epidemiological and clinical comparisons across all 12 DSM-IV psychotic diagnoses in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS).
    Psychol Med. 2021;51:607-616.
    PubMed     Abstract available

  94. ZHANG T, Xu L, Li H, Woodberry KA, et al
    Calculating individualized risk components using a mobile app-based risk calculator for clinical high risk of psychosis: findings from ShangHai At Risk for Psychosis (SHARP) program.
    Psychol Med. 2021;51:653-660.
    PubMed     Abstract available

  95. HJORTHOJ C, Larsen MO, Starzer MSK, Nordentoft M, et al
    Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016.
    Psychol Med. 2021;51:617-622.
    PubMed     Abstract available

    February 2021
  96. HUANG LY, Jackson BS, Rodrigue AL, Tamminga CA, et al
    Antisaccade error rates and gap effects in psychosis syndromes from bipolar-schizophrenia network for intermediate phenotypes 2 (B-SNIP2).
    Psychol Med. 2021 Feb 24:1-10. doi: 10.1017/S003329172000478.
    PubMed     Abstract available

  97. GRIFFITHS K, Millgate E, Egerton A, MacCabe JH, et al
    Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis.
    Psychol Med. 2021 Feb 19:1-11. doi: 10.1017/S0033291721000246.
    PubMed     Abstract available

  98. ZHANG T, Xu L, Li H, Cui H, et al
    Individualized risk components guiding antipsychotic delivery in patients with a clinical high risk of psychosis: application of a risk calculator.
    Psychol Med. 2021 Feb 17:1-10. doi: 10.1017/S0033291721000064.
    PubMed     Abstract available

  99. PIAO YH, Yun JY, Nguyen TB, Kim WS, et al
    Longitudinal symptom network structure in first-episode psychosis: a possible marker for remission.
    Psychol Med. 2021 Feb 16:1-9. doi: 10.1017/S0033291720005280.
    PubMed     Abstract available

  100. MA CF, Chan SKW, Chung YL, Ng SM, et al
    The predictive power of expressed emotion and its components in relapse of schizophrenia: a meta-analysis and meta-regression.
    Psychol Med. 2021 Feb 11:1-11. doi: 10.1017/S0033291721000209.
    PubMed     Abstract available

  101. TARRICONE I, D'Andrea G, Jongsma HE, Tosato S, et al
    Migration history and risk of psychosis: results from the multinational EU-GEI study.
    Psychol Med. 2021 Feb 10:1-13. doi: 10.1017/S003329172000495.
    PubMed     Abstract available

  102. LEGGE SE, Santoro ML, Periyasamy S, Okewole A, et al
    Genetic architecture of schizophrenia: a review of major advancements.
    Psychol Med. 2021 Feb 8:1-10. doi: 10.1017/S0033291720005334.
    PubMed     Abstract available

  103. HARROW M, Jobe TH, Tong L
    Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders.
    Psychol Med. 2021 Feb 8:1-11. doi: 10.1017/S0033291720004778.
    PubMed     Abstract available

  104. SIAFIS S, Davis JM, Leucht S
    Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based-Nomenclature.
    Psychol Med. 2021;51:522-524.

  105. MONCRIEFF J, Cohen D
    Antipsychotics as particular types of sedatives.
    Psychol Med. 2021;51:521.

  106. HERBENER ES, Harrow M
    Course and symptom and functional correlates of passivity symptoms in schizophrenia: an 18-year multi-follow-up longitudinal study.
    Psychol Med. 2021;51:503-510.
    PubMed     Abstract available

  107. LIU Y, Mendonca M, Johnson S, O'Reilly H, et al
    Testing the neurodevelopmental, trauma and developmental risk factor models of psychosis using a naturalistic experiment.
    Psychol Med. 2021;51:460-469.
    PubMed     Abstract available

  108. HJORTHOJ C, Uddin MJ, Wimberley T, Dalsgaard S, et al
    No evidence of associations between genetic liability for schizophrenia and development of cannabis use disorder.
    Psychol Med. 2021;51:479-484.
    PubMed     Abstract available

    January 2021
  109. RINGIN E, Cropley V, Zalesky A, Bruggemann J, et al
    The impact of smoking status on cognition and brain morphology in schizophrenia spectrum disorders.
    Psychol Med. 2021 Jan 14:1-19. doi: 10.1017/S0033291720005152.
    PubMed     Abstract available

  110. LIU N, Lencer R, Yang Z, Zhang W, et al
    Altered functional synchrony between gray and white matter as a novel indicator of brain system dysconnectivity in schizophrenia.
    Psychol Med. 2021 Jan 13:1-9. doi: 10.1017/S0033291720004420.
    PubMed     Abstract available

  111. SELTEN JP
    The social defeat hypothesis of schizophrenia is more topical than ever. Reply to Schalbroeck.
    Psychol Med. 2021 Jan 12:1-2. doi: 10.1017/S0033291720005176.

  112. MEYER N, Joyce DW, Karr C, de Vos M, et al
    The temporal dynamics of sleep disturbance and psychopathology in psychosis: a digital sampling study.
    Psychol Med. 2021 Jan 12:1-10. doi: 10.1017/S0033291720004857.
    PubMed     Abstract available

  113. MOORE TM, Calkins ME, Rosen AFG, Butler ER, et al
    Development of a probability calculator for psychosis risk in children, adolescents, and young adults.
    Psychol Med. 2021 Jan 12:1-9. doi: 10.1017/S0033291720005231.
    PubMed     Abstract available

  114. VIEIRA S, Gong Q, Scarpazza C, Lui S, et al
    Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis.
    Psychol Med. 2021;51:340-350.
    PubMed     Abstract available

  115. DAVIES SJC, Iwajomo T, de Oliveira C, Versloot J, et al
    The impact of psychiatric and medical comorbidity on the risk of mortality: a population-based analysis.
    Psychol Med. 2021;51:320-328.
    PubMed     Abstract available

  116. ODUOLA S, Das-Munshi J, Bourque F, Gayer-Anderson C, et al
    Change in incidence rates for psychosis in different ethnic groups in south London: findings from the Clinical Record Interactive Search-First Episode Psychosis (CRIS-FEP) study.
    Psychol Med. 2021;51:300-309.
    PubMed     Abstract available

  117. AYESA-ARRIOLA R, Ortiz-Garcia de la Foz V, Martinez-Garcia O, Setien-Suero E, et al
    Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort.
    Psychol Med. 2021;51:264-277.
    PubMed     Abstract available

  118. MARTIN-SUBERO M, Fuentes-Claramonte P, Salgado-Pineda P, Salavert J, et al
    Autobiographical memory and default mode network function in schizophrenia: an fMRI study.
    Psychol Med. 2021;51:121-128.
    PubMed     Abstract available

  119. BRUCATO G, First MB, Dishy GA, Samuel SS, et al
    Recency and intensification of positive symptoms enhance prediction of conversion to syndromal psychosis in clinical high-risk patients.
    Psychol Med. 2021;51:112-120.
    PubMed     Abstract available

  120. SMART SE, Kepinska AP, Murray RM, MacCabe JH, et al
    Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies.
    Psychol Med. 2021;51:44-53.
    PubMed     Abstract available

    December 2020
  121. BERGE D, Lesh TA, Smucny J, Carter CS, et al
    Improvement in prefrontal thalamic connectivity during the early course of the illness in recent-onset psychosis: a 12-month longitudinal follow-up resting-state fMRI study.
    Psychol Med. 2020 Dec 16:1-9. doi: 10.1017/S0033291720004808.
    PubMed     Abstract available

  122. LEE TY, Hwang WJ, Kim NS, Park I, et al
    Prediction of psychosis: model development and internal validation of a personalized risk calculator.
    Psychol Med. 2020 Dec 14:1-9. doi: 10.1017/S0033291720004675.
    PubMed     Abstract available

  123. MURRAY RM
    Listening to our critics; the care of people with psychosis.
    Psychol Med. 2020 Dec 7:1-2. doi: 10.1017/S0033291720004341.

    November 2020
  124. SARPAL DK, Tarcijonas G, Calabro FJ, Foran W, et al
    Context-specific abnormalities of the central executive network in first-episode psychosis: relationship with cognition.
    Psychol Med. 2020 Nov 23:1-10. doi: 10.1017/S0033291720004201.
    PubMed     Abstract available

  125. FAN F, Tan S, Huang J, Chen S, et al
    Functional disconnection between subsystems of the default mode network in schizophrenia.
    Psychol Med. 2020 Nov 13:1-11. doi: 10.1017/S003329172000416.
    PubMed     Abstract available

  126. GUIMOND S, Ling G, Drodge J, Matheson H, et al
    Functional connectivity associated with improvement in emotion management after cognitive enhancement therapy in early-course schizophrenia.
    Psychol Med. 2020 Nov 13:1-10. doi: 10.1017/S0033291720004110.
    PubMed     Abstract available

    The social defeat hypothesis of schizophrenia: a parsimonious explanation for multiple psychosis risk factors?
    Psychol Med. 2020 Nov 10:1-2. doi: 10.1017/S0033291720004092.

    October 2020
  128. CHRISTOPHE G, Jean-Arthur MF, Guillaume D
    Comment on Starke et al.: 'Computing schizophrenia: ethical challenges for machine learning in psychiatry': from machine learning to student learning: pedagogical challenges for psychiatry.
    Psychol Med. 2020 Oct 22:1-3. doi: 10.1017/S0033291720003906.

  129. VAN OS J, Pries LK, Ten Have M, de Graaf R, et al
    Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway.
    Psychol Med. 2020 Oct 19:1-13. doi: 10.1017/S0033291720003748.
    PubMed     Abstract available

  130. LOPEZ-MORINIGO JD, Ajnakina O, Martinez AS, Escobedo-Aedo PJ, et al
    Can metacognitive interventions improve insight in schizophrenia spectrum disorders? A systematic review and meta-analysis.
    Psychol Med. 2020 Oct 14:1-13. doi: 10.1017/S0033291720003384.
    PubMed     Abstract available

  131. HENQUET C, van Os J, Pries LK, Rauschenberg C, et al
    A replication study of JTC bias, genetic liability for psychosis and delusional ideation.
    Psychol Med. 2020 Oct 13:1-7. doi: 10.1017/S0033291720003578.
    PubMed     Abstract available

  132. BRIDGWATER M, Bachman P, Tervo-Clemmens B, Haas G, et al
    Developmental influences on symptom expression in antipsychotic-naive first-episode psychosis.
    Psychol Med. 2020 Oct 6:1-12. doi: 10.1017/S0033291720003463.
    PubMed     Abstract available

  133. CATALAN A, Tognin S, Kempton MJ, Stahl D, et al
    Relationship between jumping to conclusions and clinical outcomes in people at clinical high-risk for psychosis.
    Psychol Med. 2020 Oct 6:1-9. doi: 10.1017/S0033291720003396.
    PubMed     Abstract available

    September 2020
  134. IYER SN, Malla A, Taksal A, Maraj A, et al
    Context and contact: a comparison of patient and family engagement with early intervention services for psychosis in India and Canada.
    Psychol Med. 2020 Sep 28:1-10. doi: 10.1017/S0033291720003359.
    PubMed     Abstract available

  135. NUECHTERLEIN KH, Ventura J, Subotnik KL, Gretchen-Doorly D, et al
    A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning.
    Psychol Med. 2020 Sep 28:1-10. doi: 10.1017/S0033291720003335.
    PubMed     Abstract available

  136. NEWBURY JB, Arseneault L, Caspi A, Moffitt TE, et al
    Association between genetic and socioenvironmental risk for schizophrenia during upbringing in a UK longitudinal cohort.
    Psychol Med. 2020 Sep 25:1-11. doi: 10.1017/S0033291720003347.
    PubMed     Abstract available

  137. EHRMINGER M, Roux P, Urbach M, Andre M, et al
    The puzzle of quality of life in schizophrenia: putting the pieces together with the FACE-SZ cohort.
    Psychol Med. 2020 Sep 23:1-8. doi: 10.1017/S0033291720003311.
    PubMed     Abstract available

  138. PERALTA V, Cuesta MJ
    Schneider's first-rank symptoms have neither diagnostic value for schizophrenia nor higher clinical validity than other delusions and hallucinations in psychotic disorders.
    Psychol Med. 2020 Sep 18:1-4. doi: 10.1017/S0033291720003293.
    PubMed     Abstract available

  139. AMORETTI S, Rosa AR, Mezquida G, Cabrera B, et al
    The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses.
    Psychol Med. 2020 Sep 9:1-12. doi: 10.1017/S0033291720002226.
    PubMed     Abstract available

  140. MURRAY RM, David AS, Ajnakina O
    Prevention of psychosis: moving on from the at-risk mental state to universal primary prevention.
    Psychol Med. 2020 Sep 7:1-5. doi: 10.1017/S003329172000313.
    PubMed     Abstract available

  141. JONGSMA HE, Gayer-Anderson C, van der Ven E, Quattrone D, et al
    Authors' reply to 'on the existence of a linguistic distance in schizophrenia'.
    Psychol Med. 2020 Sep 3:1-2. doi: 10.1017/S0033291720003013.

  142. PRASAD KM, Gertler J, Tollefson S, Wood JA, et al
    Heritable anisotropy associated with cognitive impairments among patients with schizophrenia and their non-psychotic relatives in multiplex families.
    Psychol Med. 2020 Sep 3:1-12. doi: 10.1017/S0033291720002883.
    PubMed     Abstract available

  143. JIANG Y, Yao D, Zhou J, Tan Y, et al
    Characteristics of disrupted topological organization in white matter functional connectome in schizophrenia.
    Psychol Med. 2020 Sep 3:1-11. doi: 10.1017/S0033291720003141.
    PubMed     Abstract available

    August 2020
  144. THUAIRE F, Rondepierre F, Vallet GT, Jalenques I, et al
    Executive deficits in schizophrenia: mediation by processing speed and its relationships with aging.
    Psychol Med. 2020 Aug 25:1-9. doi: 10.1017/S0033291720002871.
    PubMed     Abstract available

  145. MORAN EK, Gold JM, Carter CS, MacDonald AW, et al
    Both unmedicated and medicated individuals with schizophrenia show impairments across a wide array of cognitive and reinforcement learning tasks.
    Psychol Med. 2020 Aug 17:1-11. doi: 10.1017/S003329172000286.
    PubMed     Abstract available

  146. LEMVIGH CK, Brouwer RM, Pantelis C, Jensen MH, et al
    Heritability of specific cognitive functions and associations with schizophrenia spectrum disorders using CANTAB: a nation-wide twin study.
    Psychol Med. 2020 Aug 11:1-14. doi: 10.1017/S0033291720002858.
    PubMed     Abstract available

  147. WORTINGER LA, Engen K, Barth C, Andreassen OA, et al
    Asphyxia at birth affects brain structure in patients on the schizophrenia-bipolar disorder spectrum and healthy participants.
    Psychol Med. 2020 Aug 10:1-10. doi: 10.1017/S0033291720002779.
    PubMed     Abstract available

  148. NENADIC I, Meller T, Schmitt S, Stein F, et al
    Polygenic risk for schizophrenia and schizotypal traits in non-clinical subjects.
    Psychol Med. 2020 Aug 6:1-11. doi: 10.1017/S0033291720002822.
    PubMed     Abstract available

  149. ALAMEDA L, Rodriguez V, Carr E, Aas M, et al
    A systematic review on mediators between adversity and psychosis: potential targets for treatment.
    Psychol Med. 2020 Aug 3:1-11. doi: 10.1017/S0033291720002421.
    PubMed     Abstract available

    July 2020
  150. ALHERZ M
    On the existence of a linguistic distance in schizophrenia.
    Psychol Med. 2020 Jul 23:1-2. doi: 10.1017/S0033291720002585.

  151. RODRIGUEZ-SANCHEZ JM, Setien-Suero E, Suarez-Pinilla P, Mayoral Van Son J, et al
    Ten-year course of cognition in first-episode non-affective psychosis patients: PAFIP cohort.
    Psychol Med. 2020 Jul 20:1-10. doi: 10.1017/S0033291720002408.
    PubMed     Abstract available

  152. DICKSON H, Hedges EP, Ma SY, Cullen AE, et al
    Academic achievement and schizophrenia: a systematic meta-analysis.
    Psychol Med. 2020 Jul 20:1-17. doi: 10.1017/S0033291720002354.
    PubMed     Abstract available

  153. SIDELI L, Murray RM, Schimmenti A, Corso M, et al
    Childhood adversity and psychosis: a systematic review of bio-psycho-social mediators and moderators.
    Psychol Med. 2020 Jul 6:1-22. doi: 10.1017/S0033291720002172.
    PubMed     Abstract available

    June 2020
  154. MELLER T, Schmitt S, Ettinger U, Grant P, et al
    Brain structural correlates of schizotypal signs and subclinical schizophrenia nuclear symptoms in healthy individuals.
    Psychol Med. 2020 Jun 24:1-10. doi: 10.1017/S0033291720002044.
    PubMed     Abstract available

  155. LYNHAM AJ, Cleaver SL, Jones IR, Walters JTR, et al
    A meta-analysis comparing cognitive function across the mood/psychosis diagnostic spectrum.
    Psychol Med. 2020 Jun 22:1-9. doi: 10.1017/S0033291720002020.
    PubMed     Abstract available

  156. STARKE G, De Clercq E, Borgwardt S, Elger BS, et al
    Computing schizophrenia: ethical challenges for machine learning in psychiatry.
    Psychol Med. 2020 Jun 15:1-7. doi: 10.1017/S0033291720001683.
    PubMed     Abstract available

    A major flaw in the diagnosis of schizophrenia: what happened to the Schneider's first rank symptoms.
    Psychol Med. 2020 Jun 11:1-9. doi: 10.1017/S0033291720001816.
    PubMed     Abstract available

  158. JONES HJ, Hammerton G, McCloud T, Hines LA, et al
    Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence.
    Psychol Med. 2020 Jun 9:1-8. doi: 10.1017/S0033291720001798.
    PubMed     Abstract available

  159. PATEL GH, Arkin SC, Ruiz-Betancourt DR, DeBaun HM, et al
    What you see is what you get: visual scanning failures of naturalistic social scenes in schizophrenia.
    Psychol Med. 2020 Jun 5:1-10. doi: 10.1017/S0033291720001646.
    PubMed     Abstract available

  160. BORA E
    Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis - CORRIGENDUM.
    Psychol Med. 2020 Jun 2:1. doi: 10.1017/S0033291720001701.

    May 2020
  161. LAVALLE L, Donde C, Gaweda L, Brunelin J, et al
    Impaired self-recognition in individuals with no full-blown psychotic symptoms represented across the continuum of psychosis: a meta-analysis.
    Psychol Med. 2020 May 29:1-11. doi: 10.1017/S003329172000152.
    PubMed     Abstract available

  162. VERDOUX H, Quiles C, Bon L, Chereau-Boudet I, et al
    Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers.
    Psychol Med. 2020 May 22:1-9. doi: 10.1017/S0033291720001403.
    PubMed     Abstract available

  163. HERMANS KSFM, Myin-Germeys I, Gayer-Anderson C, Kempton MJ, et al
    Elucidating negative symptoms in the daily life of individuals in the early stages of psychosis.
    Psychol Med. 2020 May 22:1-11. doi: 10.1017/S0033291720001154.
    PubMed     Abstract available

  164. HARDY A, O'Driscoll C, Steel C, van der Gaag M, et al
    A network analysis of post-traumatic stress and psychosis symptoms.
    Psychol Med. 2020 May 18:1-8. doi: 10.1017/S0033291720001300.
    PubMed     Abstract available

  165. COX ER, Marwick KFM, Hunter RW, Priller J, et al
    Dialysis and plasmapheresis for schizophrenia: a systematic review.
    Psychol Med. 2020 May 14:1-8. doi: 10.1017/S0033291720001324.
    PubMed     Abstract available

  166. HUBL D, Michel C, Schultze-Lutter F, Hauf M, et al
    Basic symptoms and gray matter volumes of patients at clinical high risk for psychosis.
    Psychol Med. 2020 May 14:1-9. doi: 10.1017/S0033291720001282.
    PubMed     Abstract available

  167. MARTIN-SUBERO M, Fuentes-Claramonte P, Salgado-Pineda P, Salavert J, et al
    Autobiographical memory and default mode network function in schizophrenia: an fMRI study-CORRIGENDUM.
    Psychol Med. 2020 May 7:1. doi: 10.1017/S0033291720001361.

    April 2020
  168. CELLA M, Price T, Corboy H, Onwumere J, et al
    Cognitive remediation for inpatients with psychosis: a systematic review and meta-analysis.
    Psychol Med. 2020 Apr 30:1-15. doi: 10.1017/S0033291720000872.
    PubMed     Abstract available

  169. SAMI M, Quattrone D, Ferraro L, Tripoli G, et al
    Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls.
    Psychol Med. 2020 Apr 28:1-9. doi: 10.1017/S0033291720000847.
    PubMed     Abstract available

  170. FUENTES-CLARAMONTE P, Lopez-Araquistain L, Sarro S, Sans-Sansa B, et al
    Brain functional correlates of formal thought disorder in schizophrenia: examining the frontal/dysexecutive hypothesis.
    Psychol Med. 2020 Apr 27:1-8. doi: 10.1017/S0033291720001063.
    PubMed     Abstract available

  171. CSUKLY G, Szabo A, Polgar P, Farkas K, et al
    Fronto-thalamic structural and effective connectivity and delusions in schizophrenia: a combined DTI/DCM study.
    Psychol Med. 2020 Apr 24:1-11. doi: 10.1017/S0033291720000859.
    PubMed     Abstract available

  172. TRIPOLI G, Quattrone D, Ferraro L, Gayer-Anderson C, et al
    Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study.
    Psychol Med. 2020 Apr 24:1-11. doi: 10.1017/S003329171900357.
    PubMed     Abstract available

  173. BALLESTEROS A, Sanchez Torres AM, Lopez-Ilundain J, Mezquida G, et al
    The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory.
    Psychol Med. 2020 Apr 24:1-10. doi: 10.1017/S003329172000080.
    PubMed     Abstract available

  174. BURGER TJ, Schirmbeck F, Vermeulen JM, Quee PJ, et al
    Association between cognitive phenotype in unaffected siblings and prospective 3- and 6-year clinical outcome in their proband affected by psychosis.
    Psychol Med. 2020 Apr 15:1-11. doi: 10.1017/S0033291720000719.
    PubMed     Abstract available

  175. ZHANG T, Xu L, Chen Y, Wei Y, et al
    Conversion to psychosis in adolescents and adults: similar proportions, different predictors.
    Psychol Med. 2020 Apr 6:1-9. doi: 10.1017/S0033291720000756.
    PubMed     Abstract available

  176. BARTOLOMEO LA, Chapman HC, Raugh IM, Strauss GP, et al
    Delay discounting in youth at clinical high-risk for psychosis and adults with schizophrenia.
    Psychol Med. 2020 Apr 6:1-8. doi: 10.1017/S0033291720000677.
    PubMed     Abstract available

  177. SALLIS HM, Croft J, Havdahl A, Jones HJ, et al
    Genetic liability to schizophrenia is associated with exposure to traumatic events in childhood.
    Psychol Med. 2020 Apr 1:1-8. doi: 10.1017/S0033291720000537.
    PubMed     Abstract available

  178. ZACHAR P, First MB, Kendler KS
    The DSM-5 proposal for attenuated psychosis syndrome: a history.
    Psychol Med. 2020 Apr 1:1-7. doi: 10.1017/S0033291720000653.
    PubMed     Abstract available

    March 2020
  179. OHI K, Otowa T, Shimada M, Sasaki T, et al
    Shared genetic etiology between anxiety disorders and psychiatric and related intermediate phenotypes.
    Psychol Med. 2020;50:692-704.
    PubMed     Abstract available

    January 2020
  180. DECROSS SN, Farabaugh AH, Holmes AJ, Ward M, et al
    Increased amygdala-visual cortex connectivity in youth with persecutory ideation.
    Psychol Med. 2020;50:273-283.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.